Abstracts/Slides: PDF/PPT zum Download ppt pdf

Art
DTG/3TC vs BIC/F/TAF bei Late Diagnosis

Art
Paso-Doble: Switch auf DTG/3TC versus BIC/F/TAF

Art
DTG/3TC trotz M184V/I erfolgreich

Sti
Einfluss von DoxyPEP auf Gonokokken-Resistenz

Schwangerschaft
LA-ART auch in Schwangerschaft möglich

PrEP
Zwei Spritzen pro Jahr schützen alle

Sexuell übertragbare Infektionen
DoxyPrEP ist effektiv

Prep
6monatige STI-Kontrollen reichen aus

Hiv Heilung
Der nächste Berlin-Patient


Willkommen bei AIDS2024 in München

Kongress-Highlights

Global Village

Kunstprojekt der Münchner Aidshilfe

Gemeinsam die HIV-Epidemie beenden – aber wie?
unterstützt von Gilead Sciences

Was haben Klima- und UNAIDS-Ziele gemeinsam?
unterstützt von Gilead Sciences

We are here until HIV and AIDS are not
unterstützt von ViiV

Münchens Queere Geschichte

München und Umgebung

LGBTIQ – Restaurants, Party, Sauna, Beratung

HIV in Deutschland – Gestern und heute

HIV-Versorgung in Deutschland

Community in Deutschland – Deutsche Aidshilfe

Medizinische Hilfe – Adressen in München und Umgebung

HIV-Schwerpunktapotheken




PDF/PPT zum Download ppt pdf

Gilead Sciences




ViiV Healthcare

CABOTEGRAVIR + RILPIVIRINE Long-acting for treatment

Long-acting Cabotegravir (CAB) plus Rilpivirine (RPV) in the first, virologically-suppressed adolescents with HIV-1 to receive an every 8-week, all-injectable regimen in a multicenter, multinational Study: IMPAACT 2017 Week 48 Outcomes*
Aditya H. et al. - Oral Presentation

View on AIDS 2024 Site

Anti-racist, anti-sexist, anti-ageist implementation science study of long-acting injectable Cabotegravir and Rilpivirine in clinic and community shows differences for women, older, and Black participants: ILANA Primary Endpoint (M12) results*
Orkin C. et al. - Poster

View on AIDS 2024 Site

Subcutaneous injections of cabotegravir + rilpivirine in virally suppressed adults with HIV-1: a substudy of the Phase 3 FLAIR study
D'Amico et al. - Oral Presentation

View Poster

Clinical Outcomes at Month 12 After Initiation of Cabotegravir and Rilpivirine Long Acting (CAB+RPV LA) in an Observational Real-World Study (BEYOND)*
Schneider S. et al. - Poster

View Poster

Perspectives of people with HIV (PWH) 12 months following a switch to cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world US study (BEYOND)
Valenti W. et al. - Poster

View Poster

12-month outcomes of cabotegravir plus rilpivirine long-acting every 2 months in a real-world setting: effectiveness, adherence to injections, and patient-reported outcomes from people with HIV-1 in the German CARLOS cohort
Jonsson-Oldenbüttel C. et al. - Poster

View Poster

Increased screening for sexually transmitted infections and HIV surrogate marker testing among long-acting injectable versus daily oral antiretroviral therapy users in the OPERA cohort
Lackey P.C. et al. - Poster

View Poster

Real-World Utilization and Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment Experienced Individuals in Europe: COMBINE-2 Cohort Study
Pozniak A. et al. - Poster

View Poster

Re-thinking 'community' in the implementation of long-acting injectable Cabotegravir and Rilpivirine: qualitative findings from the ILANA study*
Hayes R. et al. - Poster

View on AIDS 2024 Site

Adherence through the prism of long-acting injectable therapy: qualitative findings from the ILANA implementation study*
Paparini S. et al. - Poster

View on AIDS 2024 Site

Closer to a cure: mixed-methods analysis of reasons for switching to long-acting injectable Cabotegravir + Rilpivirine*
Paparini S. et al. - Poster

View on AIDS 2024 Site

"I have to feel comfortable": Attitudes towards pharmacy-administered long-acting injectable antiretroviral therapy in a sample of people with HIV*
Cocohoba J. et al. - Poster

View on AIDS 2024 Site

CABOTEGRAVIR Long-acting for prevention

Evaluation of Long-Acting Cabotegravir (CAB-LA) Pharmacokinetics During Pregnancy: A Sub-Study Analysis of the HPTN 084 Open Label Extension
Marzinke MA et al. - Oral Presentation

View on AIDS 2024 Site

Evaluation of CAB-LA Safety during pregnancy in the HPTN 084 open-label extension*
Delany-Moretlwe S. et al - Oral Presentation

View on AIDS 2024 Site

Performance characteristics of HIV RNA screening with long-acting injectable cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) in HPTN 083*
Landovitz R. et al - Oral Presentation

View on AIDS 2024 Site

Location preferences for accessing long-acting injectable pre-exposure prophylaxis (LA-PrEP) among men who have sex with men (MSM) currently using daily-oral PrEP
Glick J.L. et al. - Poster

View Poster

HIV pre-exposure prophylaxis awareness, willingness, and use among transfeminine persons with high likelihood of HIV in the United States: recent results from the Transgender Women's Internet Survey and Testing (TWIST)
Yeras D.I. et al. - Poster

View Poster

Preference for long-acting HIV prevention methods among transgender women most at risk for HIV acquisition in eastern and southern United States: findings from the LITE study
Cooney E.E. et al. - Poster

View Poster

Influencers and decision-making factors for choosing injectable PrEP among men who have sex with men and transgender men in the United States
Dandachi D. et al. - Poster

View Poster

Need for increased HIV testing prior to and during pre-exposure prophylaxis with cabotegravir long-acting injections in routine clinical care in the United States
Hsu R.K. et al. - Poster

View on AIDS 2024 Site

Pre-Exposure Prophylaxis Product Choice of Participants in HPTN 083*
Clement ME et al. - Poster

View on AIDS 2024 Site

Understanding Parental Motivations and Decision-Making for Adolescent Girls’ Participation in the long-acting cabotegravir (CAB-LA) trial – Insights from HPTN 084-1*
Ndimande-Khoza N. et al. - Poster

View on AIDS 2024 Site

Changes in sexual behavior among adolescent girls receiving long-acting injectable cabotegravir for HIV prevention; the HPTN 084-01 stud*
Mirembe B.G. et al. - Poster

View on AIDS 2024 Site

“Everyone should have access to it”: Perspectives on PrEP product choice and implementation from MSM and TGW in an injectable PrEP trial*
Psaros C. et al. - Poster

View on AIDS 2024 Site

Knowledge, awareness, feasibility, and acceptability of long-acting Cabotegravir for HIV prevention: results from the SEARCH Dynamic Choice HIV prevention trial*
Kakande E. et al. - Oral Presentation

View on AIDS 2024 Site

Early experiences with usage of injectable cabotegravir (CAB-LA) among Kenyan and Ugandan adults participating in the SEARCH Dynamic Choice HIV Prevention trial: a qualitative study*
Camlin C.S. et al. - Poster

View on AIDS 2024 Site

Intention to use long-acting PrEP among MSM in Europe – results from the PROTECT survey from Spain, Italy, Germany, France and the United Kingdom*
Jonas K. et al. - Poster

View on AIDS 2024 Site

A psycho-social weather report in the Netherlands: Mapping the internalised homonegativity "storms” and the sexual self-efficacy "sunshine" among MSM and their ecological associations with HIV care cascade*
Wang H. et al. - Poster

View on AIDS 2024 Site

Interest and intention to use long-acting injectable PrEP for HIV (LA-PrEP) among MSM and trans people in the Netherlands – results from the PROTECT Survey*
Kolstee J. et al. - Poster

View on AIDS 2024 Site

Preferences for the provision of oral and injectable PrEP among MSM and transgender persons who discontinued oral PrEP in Europe*
Zimmermann M.L.H. et al. - Poster

View on AIDS 2024 Site

Exploring the Relationship Between Comprehensive Sexual Health Prevention Measures and the Intent to Use Long-Acting PrEP among MSM*
Lozano A. et al. - Poster

View on AIDS 2024 Site

Mapping PrEP use cascades in the Netherlands under the internalised homonegativity “storm” and sexual self-efficacy “sunshine”: Where do MSM need an umbrella and where do they need sunglasses?*
Wang H. et al. - Poster

View on AIDS 2024 Site

Awareness, preferences, and attitudes towards three types of pre-exposure prophylaxis among Chinese MSM: A national cross-sectional study*
Lin H. et al. - Poster

View on AIDS 2024 Site

DOLUTEGRAVIR-based regimens

Efficacy of dolutegravir/lamivudine (DTG/3TC) in adults with HIV-1 and isolated reactive hepatitis B core antibody (anti-HBc): results from the phase 3/3b GEMINI-1/-2, STAT, TANGO, and SALSA studies
Fox D. et al. - Oral Presentation

View Poster

Non-inferior efficacy and less weight gain when switching to DTG/3TC than whens witching to BIC/FTC/TAF in virologically suppressed people with HIV (PWH): the PASODOBLE (GeSIDA 11720) randomized clinical trial*
Ryan P. et al. - Presentation

View on AIDS 2024 Site

PAIRED - PAtIent Reported Experiences and perceiveD benefit of treatment with dolutegravir/lamivudine - qualitative interviews: diverse group of people with HIV-1 (PWH) reflect on life and health
Slim J. et al. - Poster

View Poster

Real-World Effectiveness and Tolerability of the 2-Drug Regimen Dolutegravir and Lamivudine (DTG/3TC) in People Living With HIV: A Systematic Literature Review and Meta-Analysis From Clinical Practice
Fraysse J. et al. - Poster

View Poster

Viral suppression, viral failure and safety outcomes in children and adolescents on dolutegravir (DTG) in Europe and Thailand
Scott K. et al. - Oral Presentation

View Poster

Changes in body mass index in children and adolescents in Europe and Thailand before and after starting dolutegravir and compared to protease inhibitors using propensity scoring analysis
Crichton S. et al. - Poster

View Poster

Prenatal dolutegravir-based regimen use, and pregnancy and birth outcomes: data from the Antiretroviral Pregnancy Registry
Vannappagari V. et al. - Poster

View Poster

Effectiveness and durability of dolutegravir/lamivudine in older people with HIV from the Veterans Aging Cohort Study (VACS)
Yan L. N. et al. - Poster

View Poster

Effectiveness and durability of dolutegravir/rilpivirine (JULUCA) in older people with HIV from the Veterans Aging Cohort Study (VACS)
Yan L. et al. - Poster

View Poster

Switch to dolutegravir/lamivudine (DTG/3TC) in people living with HIV-1 suppressed on bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF): 96-week final analysis from the SOUND study*
Slim J. et al. - Poster

View on AIDS 2024 Site

Efficacy, safety and tolerability of switching to dolutegravir/lamivudine in virologically suppressed adults living with HIV on bictegravir/emtricitabine/tenofovir alafenamide-48-week results from the DYAD study*
Paige Rolle C. et al. - Poster

View on AIDS 2024 Site

Study of a randomised switch to DTG/RPV in subjects with HIV RNA <50c/ml and archived K103N (Wisard study): Week 96 follow-up results*
Moyle G. et al - Poster

View on AIDS 2024 Site

Differences between integrase strand transfer inhibitors on glucose tolerance: a role for mitochondrial stress*
Gisbert-Ferrandiz L. et al. - Poster

View on AIDS 2024 Site

Differential Effects of TAF, TDF and 3TC on Murine Weight, Body Composition and Adipocyte Differentiation*
García-Martínez P. et al. - Poster

View on AIDS 2024 Site

Efficacy of Dolutegravir Based Single Tablet Regimen in People with HIV who inject Drugs*
Alvarez E. et al. - Poster

View on AIDS 2024 Site

Extended efficacy and safety of dolutegravir and darunavir containing regimens at week 96 in D2EFT*
Kumarasamy N. et al. - Oral Presentation

View on AIDS 2024 Site

D2EFT Body Composition Sub-study week 96 results*
Carey D. - Poster

View on AIDS 2024 Site

Dolutegravir vs Efavirenz: Comparison and factors associated with viral blips in an acute HIV infection cohort study*
Sacdalan C. et al. - Poster

View on AIDS 2024 Site

Pipeline

Preclinical assessments of a cabotegravir prodrug predicting human dosing durations of >6 months
Baker M. et al. - Poster

View Poster

Phase 1 study of VH4524184 (VH-184), a new third-generation integrase strand transfer inhibitor (INSTI) with a unique resistance profile
Rogg L. et al. - Oral Presentation

View Poster

Pre-clinical profiles of HIV-1 capsid inhibitors VH4004280 (VH-280) and VH4011499 (VH-499)
Wang C. et al. - Poster

View Poster

Clinical pharmacokinetics and safety of orally administered VH4004280 (VH-280), a novel HIV-1 capsid inhibitor, in healthy volunteers
Griesel R. et al. - Poster

View Poster

Clinical pharmacokinetics and safety of orally administered VH4011499 (VH-499), a novel HIV-1 capsid inhibitor, in healthy volunteers
Thakkar N. et al. - Poster

View Poster

Other HIV-related data

Detailed modelling of viremia exposure does not independently predict cardiovascular disease in people with HIV
Elvstam O. et al. - Oral Presentation

View Poster

Intervention to improve HIV continuous care monitoring in public-sector HIV care sites in São Paulo, Brazil: A pre-post implementation evaluation*
Fonsi M. et al. - ePoster

View on AIDS 2024 Site

Increased biomarkers of cardiovascular disease in a long-term survivor cohort of young adults living with perinatal HIV with virologic non-suppression or metabolic syndrome*
Aurpibul L. et al. - Oral Presentation

View on AIDS 2024 Site

“A photo is not enough”: Limitations of telemedicine based on qualitative analysis of interviews with people living with HIV using this strategy in the public health system of Buenos Aires city*
Kierszenowicz T. et al. - Poster

View on AIDS 2024 Site

“They care about us”: Assessment of telemedicine by people with HIV using this strategy in the public health system of Buenos Aires city*
Kierszenowicz T. et al. - Poster

View on AIDS 2024 Site

Prioritising issues for intervention to improve the health-related quality of life of people with HIV: a network analysis*
Fuster-RuizdeApodaca M.J. et al. - Poster

View on AIDS 2024 Site

Resilient Viral Load Suppression in an Acutely-Treated Cohort of People with HIV During the COVID-19 Pandemic in Bangkok, Thailand*
Chomchey N et al. - Poster

View on AIDS 2024 Site

Inside Out: Inflammation in Acute HIV Predicts Persistent Depressive Symptoms Despite Antiretroviral Therapy*
Chavez J.V. et al. - Poster

View on AIDS 2024 Site

*denotes ViiV-supported investigator led and collaborative studies

Einige der in diesem Schreiben enthaltenen Informationen sind möglicherweise nicht in der Fachinformation zu diesem Produkt aufgeführt. Diese Information soll Ihnen lediglich bei Ihrer Entscheidungsfindung für eine angemessene Patientenversorgung dienen. Bitte beachten Sie, dass dieses Schreiben keine Empfehlungen zur Anwendung in einer Weise oder einer Indikation enthält, die nicht der Zulassung entspricht.

Um die Sicherheit unserer Produkte zu gewährleisten, bittet ViiV Healthcare Ärzte und medizinisches Fachpersonal unerwünschte Ereignisse oder Verdachtsfälle einer möglichen Überdosierung der Firma unter 0800/4529622 oder per E-Mail an viiv.med.info@viivhealthcare.com zu melden.
Wichtige Informationen zur Sicherheit entnehmen Sie bitte der Fachinformation, die Sie online unter folgender Adresse finden: https://www.viivexchange.com/de-de/.


Meldungen

  • Influenza

    04. November 2024: MF-59 adjuvantierter Influenza-Impfstoff auch für Ältere empfohlen weiter

  • Mykose

    04. November 2024: C. auris-Screening bei Aufnahme weiter

  • MPOX

    04. November 2024: Tecovirimat-Resistenz in USA weiter

  • Tuberkulose

    30. Oktober 2024: N-Acetylcystein kein Nutzen bei Eradikation, bessert aber Lungenfunktion weiter

  • Influenza

    28. Oktober 2024: RKI meldet wöchentlich Viruslast im Abwasser weiter

  • Newletter online

    Jeden Monat akutelle Informationen rund ums Thema HIV und sexuell übertragbare Erkrankungen.

    Für Ärzt_innen, Menschen mit HIV und alle Interessierten.

    Anmeldung hier

  • Robert Koch-Institut

    28. Oktober 2024: Neuer STIKO-Vorsitzender: Prof. Reinhard Berner weiter

  • MPOX

    28. Oktober 2024: Erster Fall der neuen MPOX-Variante in Deutschland weiter

  • E. coli

    28. Oktober 2024: Kolibakterien bei McDonald´s weiter

  • HIV

    22. Oktober 2024: Nierentransplantation HIV zu HIV sicher weiter

  • Leberkrebs

    21. Oktober 2024: Immun-Typen können Therapieerfolg beeinflussen weiter

  • MERS

    21. Oktober 2024: Impfstoff in Phase Ib sicher und wirksam weiter

  • Impfung

    19. Oktober 2024: Paul-Ehrlich-Institut wertet Nebenwirkungen von 100 Millionen Impfungen aus weiter

  • Virologie

    16. Oktober 2024: Neues Hochsicherheitslabor für die Marburger Virologie weiter

  • KRINKO

    14. Oktober 2024: Bundesgesundheits­ministerium beruft neue Kommission weiter

  • MPOX

    14. Oktober 2024: Impfschutz nur für wenige Monate? weiter

Ältere Meldungen weiter

Diese Website bietet aktuelle Informationen zu HIV/Aids sowie zur HIV/HCV-Koinfektion. Im Mittelpunkt stehen HIV-Test, Symptome und Auswirkungen der HIV-Infektion, Behandlung der HIV-Infektion, HIV-Medikamente mit Nebenwirkungen und Komplikationen, Aids, Hepatitis B und C. Ein Verzeichnis der Ärzte mit Schwerpunkt HIV ergänzt das Angebot.